Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

AMGEN (AMGN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Amgen : Reports Outline Genetics Study Findings from Amgen (Graphtyper enables population-scale genotyping using pangenome graphs)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 05:52pm CET

By a News Reporter-Staff News Editor at Life Science Weekly -- Researchers detail new data in Life Science Research - Genetics. According to news reporting originating from Reykjavik, Iceland, by NewsRx correspondents, research stated, "A fundamental requirement for genetic studies is an accurate determination of sequence variation. While human genome sequence diversity is increasingly well characterized, there is a need for efficient ways to use this knowledge in sequence analysis."

Our news editors obtained a quote from the research from Amgen, "Here we present Graphtyper, a publicly available novel algorithm and software for discovering and genotyping sequence variants. Graphtyper realigns short-read sequence data to a pangenome, a variation-aware graph structure that encodes sequence variation within a population by representing possible haplotypes as graph paths. Our results show that Graphtyper is fast, highly scalable, and provides sensitive and accurate genotype calls. Graphtyper genotyped 89.4 million sequence variants in the whole genomes of 28,075 Icelanders using less than 100,000 CPU days, including detailed genotyping of six human leukocyte antigen (HLA) genes."

According to the news editors, the research concluded: "We show that Graphtyper is a valuable tool in characterizing sequence variation in both small and population-scale sequencing studies."

For more information on this research see: Graphtyper enables population-scale genotyping using pangenome graphs. Nature Genetics, 2017;():. (Nature Publishing Group - www.nature.com/; Nature Genetics - www.nature.com/ng/)

The news editors report that additional information may be obtained by contacting H.P. Eggertsson, deCODE Genetics, Amgen Inc, Reykjavik, Iceland. Additional authors for this research include H. Jonsson, S. Kristmundsdottir, E. Hjartarson, B. Kehr, G. Masson, F. Zink, K.E. Hjorleifsson, A. Jonasdottir, A. Jonasdottir, I. Jonsdottir, D.F. Gudbjartsson, P. Melsted, K. Stefansson and B.V Halldorsson (see also Life Science Research - Genetics).

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1038/ng.3964. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Europe, Iceland, Genetics, Reykjavik, Life Science Research.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMGEN
01/15 AMGEN : Astellas Pharma Inc - Repatha SC Injection 420 mg Auto Mini Doser Launch..
01/11 AMGEN : FDA Approves XGEVA® denosumab For The Prevention Of Skeletal-Related Eve..
01/11 AMGEN : "Drug Delivery Device with Live Button Or User Interface Field" in Paten..
01/11 AMGEN : Patent Application Titled "Feed Media" Published Online (USPTO 201703698..
01/11 AMGEN : Patent Issued for Refolding Proteins Using a Chemically Controlled Redox..
01/11 AMGEN : Research Conducted at Amgen Has Provided New Information about Antibodie..
01/11 AMGEN : New Biologics Findings from Amgen Described (Accelerating patient access..
01/11 AMGEN : European Medicines Agency Accepts Filing for EVENITY
01/11 AMGEN : Astellas BioPharma K.K. - Application for Marketing Approval Submitted f..
01/09 U.S. pharma executives expect deals to pick up after tax overhaul
More news
News from SeekingAlpha
01/16 It's Time For The Next Generation Dividend Growth Model Portfolio
01/16 A REAL DIVIDEND GROWTH MACHINE : 2017 Portfolio Review
01/16 FDA launches new program to boost transparency of clinical data used to suppo..
01/16 Biotech Daily Digest For January 16th
01/14 THE IM-CAPITAL STRENGTH 20-STOCK UNI : Update January 2018
Financials ($)
Sales 2017 22 895 M
EBIT 2017 11 764 M
Net income 2017 8 360 M
Finance 2017 6 824 M
Yield 2017 2,44%
P/E ratio 2017 16,63
P/E ratio 2018 16,38
EV / Sales 2017 5,57x
EV / Sales 2018 5,38x
Capitalization 134 B
Chart AMGEN
Duration : Period :
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Technical analysis trends AMGEN
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 192 $
Spread / Average Target 3,8%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Executive VP, Chief Financial & Accounting Officer
Sean E. Harper Executive Vice President-Research & Development
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN6.41%134 322
JOHNSON & JOHNSON4.32%391 587
NOVARTIS1.38%225 838
ROCHE HOLDING LTD.-0.85%218 350
PFIZER0.88%217 804
MERCK AND COMPANY4.25%159 987